Skip to main content

Table 3 Percentage of free-events patients over months when associated the expression of proteins related to glycolytic metabolism with survivals (univariate analysis)

From: CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

CharacteristicsCategoriesCases (n)DFSDSSOS
24 mo60 mo120 mop24 mo60 mo120 mop24 mo60 mo120 mop
MCT1Negative17486.868.719.50.13691.468.655.40.36191.466.651.80.507
Positive1291.783.341.7 91.783.341.7 91.783.331.3 
MCT4Negative16385.766.622.00.25990.768.749.20.98289.666.745.70.364
Positive1788.257.828.9 88.263.563.5 88.252.945.4 
CD147Negative18186.766.420.50.07290.668.248.90.37490.667.345.80.085
Positive475.025.025.0 75.050.050.0 75.025.025.0 
GLUT1Negative15389.466.920.50.68392.169.247.20.56790.866.643.40.584
Positive3683.366.737.7 91.769.265.2 91.766.758.8 
CAIXNegative16384.666.118.30.00589.666.045.50.01289.664.942.90.143
Positive13100.0100.0100.0 100.0100.0100.0 92.384.675.2 
  1. DFS Disease-free survival, DSS Disease-specific survival, OS Overall survival, mo Months. Significant values are shown in bold